809 abstracts found.



Results filter



Introduction: Stratified medicine

Year:

Session type:

Alan Ashworth1
1The Institute of Cancer Research, London, UK



Imaging tumour metabolism using hyperpolarised 13C magnetic resonance spectroscopy

Year:

Session type:

Kevin Brindle1
1University of Cambridge, Cambridge, UK



Introduction: The diagnostic and therapeutic potential of the tumour microenvironment

Year:

Session type:

Thorsten Hagemann1
1Barts Cancer Institute, London, UK



Human cancer epigenetics

Year:

Session type:

Manel Esteller1
IDIBELLBellvitge Biomedical Research Institute



Modelling the role of the tumour microenvironment in therapeutic response

Year:

Session type:

Michael Hemann1
1MIT, Cambridge, MA, USA



The immune suppressive tumour stromal cell expressing Fibroblast Activation Protein (FAP) belongs to a cellular lineage mediating essential physiological functions

Year:

Session type:

Douglas Fearon1
1Cancer Research UK Cambridge Research Institute, Cambridge, UK



Post-translational chemokine modification prevents intratumoral infiltration of antigen-specific T cells

Year:

Session type:

Vincenzo Bronte1
1Verona University, Verona, Italy



HDAC inhibitors: From bench to clinic, and back again

Year:

Session type:

Nicholas La Thangue1
1University of Oxford, Oxford, UK



Epigenetic plasticity and the basis of human cancer

Year:

Session type:

Andrew Feinberg1
1Johns Hopkins University, Baltimore, MD, USA



Introduction: Predictive mouse models of human cancer

Year:

Session type:

David Tuveson1
1Cancer Research UK, Cambridge, UK



Can genetic risk profiling in colorectal cancer guide prevention and screening?

Year:

Session type:

Malcolm Dunlop1
1University of Edinburgh, Edinburgh, UK



Harnessing transposons for cancer gene discovery

Year:

Session type:

Neal Copeland1
1Institute of Molecular and Cell Biology, Singapore, Singapore



Introduction: EMT in cancer, development and tissue maintenance

Year:

Session type:

Nick Hastie1
1MRC Human Genetics Unit, Edinburgh, UK



Studying therapy response and resistance in mouse models of human breast cancer

Year:

Session type:

Jos Jonkers1
1Netherlands Cancer Institute, Amsterdam, The Netherlands



MicroRNAs, EMT and cancer stem cells

Year:

Session type:

Thomas Brabletz1
1University of Freiburg, Freiburg, Germany



Modelling and targeting differentiation-state heterogeneity in cancer

Year:

Session type:

Piyush Gupta1
1Whitehead Institute for Biomedical Research, Cambridge, MA, USA



Intravital imaging of metastasis

Year:

Session type:

Erik Sahai1
1Cancer Research UK London Research Institute, London, UK



Introduction: Metabolism and cancer

Year:

Session type:

Eyal Gottlieb1
1Beatson Institute for Cancer Research, Glasgow, UK



Metabolic alterations to support cancer cell proliferation

Year:

Session type:

Matthew Vander Heiden1
1Koch Institute at MIT, Cambridge, MA, USA



Predicting selective drug targets in cancer through metabolic networks

Year:

Session type:

Tomer Shlomi1
1Technion, Haifa, Israel



Introduction: Transformational impact of symptom control for cancer patients

Year:

Session type:

Peter Selby1
1Cancer Research UK Centre, Leeds, UK



Overview on how symptom control and dealing with toxicity has changed over the last decade and enabled the delivery of more complex and effective treatment

Year:

Session type:

Martin Gore1
1Royal Marsden Hospital, London, UK



Cancer and bone – minimizing the clinical impact of bone complications

Year:

Session type:

Robert Coleman1
1Weston Park Hospital, Sheffield, UK



Work and cancer survivors

Year:

Session type:

Michael Feuerstein1
1Uniformed Services University, Bethesda Maryland, USA



Introduction: Colorectal cancer screening in the United Kingdom: Successes, failures and future developments

Year:

Session type:

Robert Steele1
1University of Dundee, Dundee, UK



Food, nutrition, physical activity, and cancer prevention: evidence and recommendations

Year:

Session type:

Martin Wiseman1
1WCRF International, London, UK

SNW1 as a novel regulator of BMP signalling during early embryonic development

Year:

Session type:

Sabine Reichert1, Mary Y. Wu1, Marie-Christine Ramel1, Caroline S. Hill1
1CR-UK London Research Institute, London, UK



Chemoprevention successes and surprises

Year:

Session type:

John Baron1
1University of North Carolina, Chapel Hill, NC, USA

Elevated stromal Foxp3+ regulatory T cells combined with low density CD8+ cytotoxic T cells are associated with colorectal metastatic tumour progression

Year:

Session type:

Helen Angell1, Xiu Huan Yap2, Sunita Mistry2, Marie Cumberbatch2, Neil Gray2, Chris Womack2, Sue Watson3, David Pritchard1, Robert Wilkinson4
1School of Pharmacy, University of Nottingham, Nottingham, UK, 2Molecular Pathology Group, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, UK, 3School of Medical and Surgical Sciences, University of Nottingham, Nottingham, UK, 4Innovative Medicines Oncology, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, UK

HDAC6 inhibition down regulates c-FLIP and induces caspase 8-dependent apoptosis in colorectal cancer cells

Year:

Session type:

Emma Kerr1, Caitriona Holohan1, Kirsty McLaughlin1, Joel Riley1, Patrick Johnston1, Daniel Longley1
1Centre for Cancer Research and Cell Biology, Belfast, UK

Small molecule inhibitors of metabolic flux as potential antitumour agents

Year:

Session type:

Jonathan Williams1,2, Adrian Harris2, Angela Russell1,3, Carole Bataille1, Stephen Davies1, Gu Liu1, Andrew Lomas2,3, Anassuya Ramachandran2
1Chemistry Research Laboratory, University of Oxford, Oxford, UK, 2Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK, 3Department of Pharmacology, University of Oxford, Oxford, UK

Novel mouse models for specific targeting and visualisation of lymphatic vasculature in vivo

Year:

Session type:

Lukas Stanczuk1, Florence Tatin1, Taija Makinen1
1CR-UK London Research Institute, London, UK

Wnt/ β-catenin regulation of embryonic NANOG (NANOG1) defines colorectal cancer stem cells and modulated by c-Jun/TCF4 transcriptional activity

Year:

Session type:

Elsayed Ibrahim1, Abdolrahman Shams Nateri1
1University of Nottingham, Nottingham, UK



Introduction: Epigenetics and cancer

Year:

Session type:

Peter D. Adams1
1Institute of Cancer Sciences, Glasgow, UK



Tailoring treatment in lung cancer

Year:

Session type:

Jean-Charles Soria1
1Institut Gustave Roussy, Villejuif, France



Parallel clinical trials in cells, mice and patients to define the genetic bases of response and resistance to targeted therapies in CRCs

Year:

Session type:

Alberto Bardelli1
TOUniversity of Torino-Medical School, Candiolo



The challenges for the implementation of molecular diagnostics in the clinical setting

Year:

Session type:

David Gonzalez de Castro1
1The Institute of Cancer Research, London, UK

Notch signalling mediates myofibroblast differentiation of carcinoma-associated fibroblasts

Year:

Session type:

Ahmet Acar1,2, Göran Landberg2, Akira Orimo1
1CR-UK Stromal-Tumour Interaction Group, Paterson Institute for Cancer Research, Manchester, UK, 2Breakthrough Breast Cancer Research Unit, School of Cancer, Enabling Sciences and Technology, University of Manchester, Manchester Academic Health Science Centre, Paterson Institute for Cancer Researc, Manchester, UK

TLR2 and TLR4 expression in inflammatory gastric lesion before and after  Helicobacter pylori eradication therapy

Year:

Session type:

Aline Cristina Targa Cadamuro1, Patrícia Biselli2, Rodrigo Castro2, Fausto Nasser3, Patrícia Fucuta3, Edla Bedin Polsinelli3, Kenji Miyasaki3, André Volpatto3,4, Ricardo Acayaba4, Eny Maria Goloni Bertollo2, Ana Elizabete Silva1
1UNESP - São Paulo State University, São José do Rio Preto, Brazil, 2Famerp - School of Medicine, São José do Rio Preto, Brazil, 3Base Hospital, São José do Rio Preto, Brazil, 4João Paulo II Hospital, São José do Rio Preto, Brazil

K-ras 146, N-ras 12/13, and N-ras 61 mutations in Quasar1 stage II/III colorectal cancers occur in 6% of cases.  A small but important group?

Year:

Session type:

Katie Southward1, Morag Taylor1, Kelly Handley2, Laura Magill2, Phil Chambers1, Claire Beaumont1, Susan Richman1, Matt Seymour3, David Kerr4, Richard Gray2, Phil Quirke1
1Leeds Institute of Molecular Medicine, Leeds, UK, 2Birmingham Clinical Trials Unit, Birmingham, UK, 3Cancer Research UK Clinical Centre, Leeds, UK, 4Department of Clinical Pharmacology, Oxford, UK

Imaging the development of functional tumour vasculature in vivo in preclinical models

Year:

Session type:

Gemma Marston1, Nicola Ingram1, Mark Hull1, Alex Markham1, Pam Jones1, P. Louise Coletta1
1University of Leeds, Leeds, UK

Defining a spatially restricted aPKC/ERK phosphoproteome

Year:

Session type:

Nick Peel1, Carine Rosse1, Katrina Boeckeler1, Peter Parker1
1CR-UK London Research Institute, London, UK

Lgr5 stem cells in self-renewal and cancer

Year:

Session type:

Hans Clevers1
1Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences & University Medical Centre Utrecht, Utrecht, The Netherlands

Analysing paired array-comparative genomic hybridisation and gene expression microarray data: A novel method to infer gene relationships

Year:

Session type:

Xin Yi Goh1,2, Richard Newton3, Lorenz Wernisch3, Rebecca Fitzgerald1
1MRC Cancer Cell Unit, Cambridge, UK, 2University of Cambridge, Cambridge, UK, 3MRC Biostatistics Unit, Cambridge, UK

Chemoprevention: Why do we keep getting it wrong?

Year:

Session type:

John Potter1
1University of Washington, Seattle, USA, 2Massey University, Wellington, New Zealand

Modelling drug sensitivity and resistance in tumour-derived cell lines

Year:

Session type:

Jeff Settleman1
1Genentech, South San Francisco, USA

Improving cancer survival in England:  Driving for the best

Year:

Session type:

Sir Mike Richards1
1National Clinical Director for Cancer and End of Life Care, England, UK

Genome stability: From worms to human disease

Year:

Session type:

Simon Boulton1
1Cancer Research UK, London Research Institute, South Mimms, UK

TOR signalling and the control of cell growth

Year:

Session type:

Michael N. Hall1
1Biozentrum, University of Basel, Basel, Switzerland

Cancer survivorship: Surveying the landscape of cancer survivorship research

Year:

Session type:

Eva Grunfeld1
1University of Toronto, Toronto, Canada